Dietary fat modifies the postprandial inflammatory state in subjects with metabolic syndrome: the LIPGENE study

Mol Nutr Food Res. 2012 Jun;56(6):854-65. doi: 10.1002/mnfr.201200096.


Scope: Our aim was to investigate whether the inflammatory state associated to metabolic syndrome (MetS) patients is affected by diets with different fat quality and quantity.

Methods and results: Seventy-five subjects from LIPGENE cohort were included in this feeding trial and randomly assigned to one of four diets: high saturated fatty acids (HSFA); high monounsaturated fatty acids (HMUFA) and two low-fat, high complex carbohydrate (LFHCC) diets, supplemented with long-chain n-3 polyunsaturated fatty acids (LFHCC n-3) or placebo (LFHCC), for 12 weeks each. A postprandial fat challenge, reflecting the intervention dietary fat composition, was conducted post-intervention. The HMUFA diet significantly reduced postprandial nuclear transcription factor-kappaB (NF-kB) activity and the nuclear p65 protein levels relative to fasting values (p < 0.05). Furthermore, we observed a postprandial decrease in this protein with the HMUFA diet compared with the HSFA and LFHCC diets (p < 0.05). The postprandial response of inhibitory molecule from NF-kB mRNA levels increased with the HMUFA diet compared with the HSFA and LFHCC n-3 diets (p < 0.05). Postprandial tumor necrosis factor-α and Metalloproteinase 9 mRNA levels were also reduced after the HMUFA diet compared with the HSFA diet (p < 0.05).

Conclusion: Our results indicate that the long-term consumption of a healthy diet model with HMUFA attenuates the postprandial inflammatory state associated with MetS.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cohort Studies
  • Diet, Fat-Restricted
  • Diet, High-Fat / adverse effects
  • Dietary Fats / administration & dosage
  • Dietary Fats / adverse effects
  • Dietary Fats / therapeutic use*
  • Fatty Acids, Monounsaturated / administration & dosage
  • Fatty Acids, Monounsaturated / therapeutic use
  • Fatty Acids, Omega-3 / administration & dosage
  • Fatty Acids, Omega-3 / therapeutic use
  • Female
  • Gene Expression Regulation
  • Humans
  • Leukocytes, Mononuclear / metabolism
  • Male
  • Matrix Metalloproteinase 9 / blood
  • Matrix Metalloproteinase 9 / genetics
  • Matrix Metalloproteinase 9 / metabolism
  • Metabolic Syndrome / blood
  • Metabolic Syndrome / diet therapy*
  • Metabolic Syndrome / immunology*
  • Metabolic Syndrome / metabolism
  • Middle Aged
  • NF-kappa B / blood
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Patient Compliance
  • Postprandial Period
  • RNA, Messenger / metabolism
  • Transcription Factor RelA / blood
  • Tumor Necrosis Factor-alpha / blood
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / metabolism


  • Dietary Fats
  • Fatty Acids, Monounsaturated
  • Fatty Acids, Omega-3
  • NF-kappa B
  • RELA protein, human
  • RNA, Messenger
  • Transcription Factor RelA
  • Tumor Necrosis Factor-alpha
  • Matrix Metalloproteinase 9